ArticleJournal for immunotherapy of cancer2019

Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200.

Daruka Mahadevan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.